Clinical Trials Browser

Unknown × Observational × pembrolizumab × Clear all

NCT03458455 2023-11-01

TREATMENT

Brain Neoplasms

NCT06100796 2023-10-25

NSCLC

Diabetes Mellitus

NCT05418660 2023-09-18

I-STOP

Carcinoma, Non-Small-Cell Lung

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT04359199 2023-02-10

QUASAR

Squamous Cell Carcinoma of Head and Neck, Deglutition Disorders, Head and Neck Neoplasms, Oropharyngeal Neoplasms

NCT05578170 2023-02-03

PROBES

Squamous Cell Carcinoma of Head and Neck

NCT04740996 2022-02-07

Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04465942 2021-08-23

Immunotherapy in Lung Cancer: Treatment After IO Cessation.

Carcinoma, Non-Small-Cell Lung

NCT04860076 2021-04-26

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

DermatologicThoracic

Lung Neoplasms, Melanoma

NCT03373955 2021-03-18

A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04771715 2021-02-25

Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer

Gastrointestinal

Advanced Colorectal Carcinoma

NCT04683445 2020-12-24

Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

Breast Neoplasms

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Carcinoma, Non-Small-Cell Lung

NCT04306042 2020-03-12

A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy

Lung Squamous Cell Carcinoma Stage IV